4 relations: Elafibranor, GlaxoSmithKline, GW501516, Peroxisome proliferator-activated receptor.
Elafibranor
Elafibranor (INN, code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
New!!: GW0742 and Elafibranor · See more »
GlaxoSmithKline
GlaxoSmithKline plc (GSK) is a British pharmaceutical company headquartered in Brentford, London.
New!!: GW0742 and GlaxoSmithKline · See more »
GW501516
GW501516 (also known as GW-501,516, GW1516, GSK-516 and on the black market as Endurobol) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s, was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases, and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs.
New!!: GW0742 and GW501516 · See more »
Peroxisome proliferator-activated receptor
In the field of molecular biology, the peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes.
New!!: GW0742 and Peroxisome proliferator-activated receptor · See more »
Redirects here:
C21H17F4NO3S2, GW 610742, GW-0742, GW610742.